Quince Therapeutics (NASDAQ:QNCX) Upgraded to “Hold” at Wall Street Zen

Posted by Brenda Bartman on May 18th, 2026

Wall Street Zen upgraded shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) from a sell rating to a hold rating in a report issued on Sunday.

Several other analysts have also recently issued reports on the company. Lucid Cap Mkts cut Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a report on Friday, January 30th. Weiss Ratings cut Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 29th. Maxim Group cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Finally, Citigroup cut Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $65.00.

Check Out Our Latest Analysis on QNCX

Quince Therapeutics Price Performance

Shares of QNCX opened at $1.15 on Friday. The stock has a market capitalization of $18.75 million, a price-to-earnings ratio of -0.11 and a beta of 1.45. Quince Therapeutics has a 1 year low of $0.80 and a 1 year high of $45.50. The business’s 50 day simple moving average is $1.17 and its 200-day simple moving average is $14.47.

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.71.

Hedge Funds Weigh In On Quince Therapeutics

Several large investors have recently modified their holdings of QNCX. XTX Topco Ltd bought a new position in shares of Quince Therapeutics during the 2nd quarter valued at approximately $37,000. Nantahala Capital Management LLC bought a new position in shares of Quince Therapeutics during the 2nd quarter valued at approximately $4,172,000. Bridgeway Capital Management LLC increased its position in shares of Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Quince Therapeutics by 21.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock valued at $2,874,000 after purchasing an additional 309,349 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in Quince Therapeutics by 158.0% in the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after acquiring an additional 53,417 shares during the last quarter. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

(Get Free Report)

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.